HIV vaccine candidate shows promise in early trial
NCT ID NCT03284710
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental HIV vaccine in 132 healthy, HIV-negative adults. The vaccine uses a harmless virus (ALVAC) to deliver HIV proteins, plus a protein boost (gp120) with an adjuvant to strengthen the immune response. The main goals were to check safety and measure whether the vaccine triggers antibodies against HIV. Results will help decide if this approach should move to larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALVAC-HIV (vCP2438) and bivalent subtype C gp120 with MF59 or alum adjuvant
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that trains the immune system to fight the virus.
What could go wrong
This is an early-phase trial (1/2a) focused on safety and immune response, not on preventing HIV infection. Many HIV vaccine candidates have failed in later trials, so success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Tembisa CRS
Johannesburg, Gauteng, 1632, South Africa
-
Emavundleni CRS
Cape Town, Western Cape, 7750, South Africa
-
Polana Canico Health Research and Training Center (CISPOC), National Institute of Health (INS) CRS
Maputo, Mozambique
-
Seke South CRS
Chitungwiza, Mashonaland East Province, Zimbabwe
-
Soweto HVTN CRS
Johannesburg, Gauteng, 1862, South Africa
-
eThekwini CRS
Durban, KwaZulu-Natal, 4013, South Africa